Proliferating cell nuclear antigen in breast lesions: Correlation of c-erbB-2 oncoprotein and EGF receptor and its clinicopathological significance in breast cancer

1992 ◽  
Vol 421 (3) ◽  
pp. 193-202 ◽  
Author(s):  
Prashanta Shrestha ◽  
Kazuto Yamada ◽  
Tomio Wada ◽  
Shigenari Maeda ◽  
Masahiro Watatani ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Proliferating Cell Nuclear Antigen ◽  
Egf Receptor ◽  
Nuclear Antigen ◽  
Breast Lesions ◽  
Clinicopathological Significance ◽  
Proliferating Cell

scholarly journals A Peptide Mimicking a Region in Proliferating Cell Nuclear Antigen Specific to Key Protein Interactions Is Cytotoxic to Breast Cancer

2014 ◽  
Vol 87 (2) ◽  
pp. 263-276 ◽  
Author(s):  
Shanna J. Smith ◽  
Long Gu ◽  
Elizabeth A. Phipps ◽  
Lacey E. Dobrolecki ◽  
Karla S. Mabrey ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Protein Interactions ◽  
Proliferating Cell Nuclear Antigen ◽  
Nuclear Antigen ◽  
Proliferating Cell

Controlled Release of Epidermal Growth Factor from Hydrogels Accelerates Wound Healing in Diabetic Rats

2012 ◽  
Vol 102 (2) ◽  
pp. 89-98 ◽  
Author(s):  
Guojuan Lao ◽  
Li Yan ◽  
Chuan Yang ◽  
Liming Zhang ◽  
Shaoling Zhang ◽  
...  
Keyword(s):  
Wound Healing ◽  
Proliferating Cell Nuclear Antigen ◽  
Egf Receptor ◽  
B Cell Lymphoma ◽  
Diabetic Rats ◽  
Nuclear Antigen ◽  
Therapeutic Effects ◽  
Hydrogel Matrix ◽  
Epidermal Growth ◽  
Proliferating Cell

Background: We sought to develop new recombinant human epidermal growth factor (rhEGF)–containing hydrogels and to investigate their biological activity and therapeutic effects on wound healing in diabetic rats. Methods: Levels of rhEGF released from hydrogels were measured by enzyme-linked immunosorbent assay. The cellular proliferating activity of released rhEGF was evaluated by MTT assay. Fifty-six wounded diabetic rats were randomly divided into four groups with different topical treatment daily. The therapeutic effects were evaluated by wound area measurement, histologic analysis, immunohistochemical assessment of proliferating cell nuclear antigen and B-cell lymphoma/leukemia-2, and Western blotting of EGF receptor. Results: The rhEGF released from the hydrogel matrix kept its bioactivity on stimulating proliferation of the BALB/c3T3 cell line. Wound closure rates on postoperative day 14 were 75.8% in the negative control group, 82.83% in the group treated with hydrogel matrix, 85.87% in the group treated with rhEGF-containing hydrogel, and 81.18% in the group treated with rhEGF solution. Compared with hydrogel matrix, rhEGF-containing hydrogel had an additional effect on induction of EGF receptor expression (P < .05). Compared with negative controls, protein expression of B-cell lymphoma/leukemia-2 was higher in the rhEGF-containing groups (P < .05). Proliferating cell nuclear antigen was induced at its highest level on day 7 in the rhEGF-containing hydrogel–treated group (P < .05). Conclusions: These data from in vitro release and diabetic animal models highlight the efficacy of hydrogels as a controlled releasing system for topical application of EGFs. The rhEGF-containing hydrogel we developed holds the merits of prolonged and sustained releasing of bioactive rhEGF and therapeutic potential in enhancing diabetic wound healing. (J Am Podiatr Med Assoc 102(2): 89–98, 2012)

scholarly journals The Prognostic Implications of Macrophages Expressing Proliferating Cell Nuclear Antigen in Breast Cancer Depend on Immune Context

PLoS ONE ◽  
2013 ◽  
Vol 8 (10) ◽  
pp. e79114 ◽  
Author(s):  
Michael J. Campbell ◽  
Denise Wolf ◽  
Rita A. Mukhtar ◽  
Vickram Tandon ◽  
Christina Yau ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Proliferating Cell Nuclear Antigen ◽  
Nuclear Antigen ◽  
Prognostic Implications ◽  
Proliferating Cell
Sign in / Sign up

Export Citation Format

Share Document